Arch Oncology is a biotechnology company focused on developing next-generation antibody therapeutics to treat cancer. The company specializes in creating highly differentiated anti-CD47 antibodies that not only block the 'eat signal' but also directly kill tumor cells and induce Immunogenic Cell Death (ICD). These antibodies preferentially bind to tumor cells, especially in acidic microenvironments, thereby minimizing damage to normal cells. Arch Oncology operates in the oncology market, primarily serving patients living with cancer. The business model revolves around research and development (R&D) of these advanced therapeutics, aiming to bring them through clinical trials and eventually to market. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of approved therapies.

Keywords: biotechnology, oncology, anti-CD47, antibodies, cancer treatment, tumor cells, immunogenic cell death, clinical trials, R&D, therapeutics.